Evidence map›Paper›PMID 35853193›Full record

ReviewJCO global oncology2022

Adopting Health Economic Research in Radiation Oncology: A Perspective From Low- or Middle-Income Countries.

Shwetabh Sinha, Sarbani Ghosh Laskar, Tabassum Wadasadawala, Rahul Krishnatry, Yolande Lievens, Jai Prakash Agarwal

Abstract readReview
In one paragraph

Review in JCO global oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Real-world data and evidence: pioneering frontiers in precision oncology.Journal of Zhejiang University. Science. B · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shwetabh SinhaDepartment of Radiation Oncology, Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.ORCID 0000-0003-3369-3870
Sarbani Ghosh LaskarDepartment of Radiation Oncology, Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.ORCID 0000-0003-0744-4838
Tabassum WadasadawalaDepartment of Radiation Oncology, Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.ORCID 0000-0003-2167-420X
Rahul KrishnatryDepartment of Radiation Oncology, Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.ORCID 0000-0003-4511-7782
Yolande LievensDepartment of Radiation Oncology, Ghent University Hospital, Ghent, Belgium.ORCID 0000-0002-9157-3730
Jai Prakash AgarwalDepartment of Radiation Oncology, Homi Bhabha National Institute, Tata Memorial Centre, Mumbai, India.ORCID 0000-0003-0430-8558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Establishing a new radiation therapy (RT) setup is resource-intensive as it involves substantial capital costs and the recruitment of a skilled workforce. It is essential to incorporate health economic analysis that estimates recurring and nonrecurring expenses on the basis of the national and local needs, infrastructure, and future projections. RT costing exercises can be especially relevant for low- or middle-income countries (LMICs) with more than 70% of the global cancer burden, with access to < 20% of the available resources. This review article summarizes the scope of RT costing exercises in LMICs, the hurdles in conducting them, and possible ways to circumvent them. The purpose of performing costing studies in RT lies in their utility to improve the efficiency of the investment while at the same time helping to address the issues of uniformity and equitable distribution of resources. This will help assess the net benefit from RT in terms of utility and outcome-linked parameters like Quality-Adjusted Life Years. There are numerous barriers to conducting economic evaluations in LMICs, including the lack of national costing values for equipment, data on manpower salary, cost for public and private setups, and indirect costs. The situation is further complicated because of the nonuniform pay structure, lack of an organizational framework, robust real-world data on outcomes, and nonavailability of country-specific reference utility values. Collaborative national efforts are required to collect all elements required to perform health technology assessments. Information from the national and hospital databases can be made available in the public domain to ease access and broader adoption of health economic end points in routine care. Although resource-intensive at the onset, costing studies and health economic assessments are essential for improving the coverage and quality of RT in LMICs.

Indexed as

Developing CountriesRadiation OncologyCost-Benefit AnalysisEconomics, MedicalIncome

Identifiers

PMID35853193
PMCPMC9812487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.